Press releaseAd hoc announcement pursuant to Art. 53 LR Following solid sales growth of 2.6% in the first half of 2024, Galenica grew more strongly again in the third quarter and generated net sales of CHF 2,864.8 million to the end of September 2024. With growth of 4.1%, Galenica outperformed the growth of the overall pharmaceutical market (+2.9%, [ … ]

Press releaseAd hoc announcement pursuant to Art. 53 LR Galenica Group sales grew by 2.6% to CHF 1,900.0 million in the first half of 2024. Both the “Products & Care” segment and the “Logistics & IT” segment contributed to the sales growth, with growth of 3.1% and 3.0% respectively. As a result, Galenica Group sales developed more dynamical [ … ]

Press releaseAd hoc announcement pursuant to Art. 53 LR The Galenica Group made a good start to the new year with sales growth of 4.8% to CHF 1,255.5 million in the first four months of 2024. All Service Units performed well and contributed to the good sales performance.  The sales growth is based on a positive development of the pharmaceutical ma [ … ]

Press releaseAd hoc announcement pursuant to Art. 53 LR The Galenica Group achieved strong growth with an increase in sales of 4.4% in the 2023 financial year and generated consolidated net sales of CHF 3,746.0 million. Adjusted for the extraordinary sales related to COVID-19 (self-tests, COVID-19 vaccinations and rapid tests) in the prior-year per [ … ]

Press releaseAd hoc announcement pursuant to Art. 53 LR Galenica Group sales performed well in 2023, growing by 4.4% to CHF 3,746.0 million. As expected, sales growth of 3.3% in the second half of 2023 was lower than the +5.5% recorded in the first half due to the exceptionally strong comparative period in the second half of 2022, when there was a  [ … ]